ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2026
The TRIM14-KIF1B Axis Drives Renal Injury in Diabetic Nephropathy Through TLR4/NF-κB Pathway Modulation.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Esculetin Attenuates Inflammation and Fibrosis to Prevent AKI-to-CKD Transition in Adenine-Induced Renal Injury by Inhibiting the EGFR/SRC/PI3K/AKT/NF-κB Signaling Axis.Pharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic nephropathy (DN), a major contributor to end-stage renal disease, remains poorly understood at the molecular level. While the roles of TRIM proteins in metabolic diseases are emerging, the specific function of Tripartite Motif Containing 14 (TRIM14) in DN and its novel interaction with Kinesin Family Member 1B (KIF1B) have not been explored. This study aims to investigate this uncharted mechanistic axis. Methods: A rat DN model was established using a high-fat diet and streptozotocin injection. Transcriptome sequencing, functional enrichment, and protein-protein interaction (PPI) network analyses were performed to identify key regulatory genes and novel interactions. In vitro, high-glucose-exposed HK-2 cells were used for functional assays. The interaction between TRIM14 and KIF1B was validated by co-immunoprecipitation (Co-IP) and immunofluorescence. TRIM14 expression was also assessed in DN patient blood samples via qPCR. Results: Transcriptomic profiling revealed significant enrichment of immune and metabolic pathways in DN, with TRIM14 emerging as a central regulatory gene. TRIM14 expression was markedly elevated in DN rat kidneys (approximately 2-fold increase, p < 0.001), high-glucose-stimulated HK-2 cells (2-fold increase, p < 0.01), and DN patient blood. Knockdown of TRIM14 significantly mitigated high-glucose-induced apoptosis, oxidative stress, and inflammation in HK-2 cells, partially by suppressing the TLR4/NF-κB pathway. Crucially, PPI analysis and Co-IP confirmed KIF1B as a novel and direct TRIM14 interactor, with TRIM14 positively regulating KIF1B expression and co-localizing in HK-2 cells. Conclusion: We report for the first time that the TRIM14-KIF1B axis acts as a key driver of renal injury in DN. TRIM14 exacerbates tubular epithelial cell damage via KIF1B modulation and TLR4/NF-κB activation. TRIM14 represents a promising diagnostic biomarker and therapeutic target for DN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.